Kyverna Therapeutics

Medical Director/Sr. Medical Director, Clinical Development

Kyverna Therapeutics  •  Remote  •  11 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.

Title: Medical Director/Sr. Medical Director, Clinical Development

Location: Remote or Hybrid

Reports To: SVP, Clinical Development & Medical Affairs

Responsibilities

  • Serve as the physician lead for CAR T-cell therapy clinical trials in autoimmune disease indications, in partnership with internal and external cross-functional teams.
  • Oversee medical monitoring of clinical trials, including engagement with site investigators and external medical monitors.
  • Partner with clinical operations, biometrics, regulatory, and commercial teams to ensure alignment on strategy and execution.
  • Lead design, execution, and interpretation of clinical trials across assigned program
  • Provide medical and scientific input into clinical development plans, study protocols, investigator brochures, and regulatory submissions.
  • Medical review, analysis, and interpretation of safety, efficacy, and PK and biomarker data.
  • Development of clinical trial documents including protocols, ICFs, clinical development plans, and publications.
  • Lead the development of clinical sections of regulatory documents including the IB, safety updates, clinical study reports, and responses to Health Authorities.
  • Actively engage with external investigators and researchers to identify, evaluate, and support investigator sponsored studies and drive research collaborations.

Qualifications

  • MD, DO, (or ex-US equivalent) or MD-PhD degree required.
  • 5+ years of clinical research experience with 3+ years of industry experience in late phase clinical development involved in the design and execution of clinical trials. Experience in late-stage clinical development preferred.
  • Specialty training in neurology, rheumatology, nephrology and/or industry experience in clinical development of cell therapies and/or therapies for autoimmune diseases is highly preferred.
  • Proven ability to interpret, discuss and present efficacy and safety data.
  • Strong knowledge of GCP/ICH, clinical trial design, clinical development processes, and regulatory requirements.
  • Strong ability to communicate and establish effective working relationship with investigators, collaborators, scientific advisors, CROs, and corporate partners.

The salary range for this position is from $330,000 to 370,000 USD annually. This salary range is an estimate of what we reasonably expect to pay for this posted position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data.  This position is also eligible for bonus, benefits, and participation in Company’s stock plan.

Kyverna Therapeutics

About Kyverna Therapeutics

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.

Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Industry
Biotech & Life Sciences
Company Size
51-200 employees
Headquarters
Emeryville, California
Year Founded
2018
Social Media